These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

746 related articles for article (PubMed ID: 17977555)

  • 1. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
    Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
    J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
    Clemente JC; Hemrajani R; Blum LE; Goodenow MM; Dunn BM
    Biochemistry; 2003 Dec; 42(51):15029-35. PubMed ID: 14690411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.
    Ode H; Ota M; Neya S; Hata M; Sugiura W; Hoshino T
    J Phys Chem B; 2005 Jan; 109(1):565-74. PubMed ID: 16851048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
    Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
    J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.
    Ode H; Matsuyama S; Hata M; Hoshino T; Kakizawa J; Sugiura W
    J Med Chem; 2007 Apr; 50(8):1768-77. PubMed ID: 17367119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.
    Bihani SC; Das A; Prashar V; Ferrer JL; Hosur MV
    Biochem Biophys Res Commun; 2009 Nov; 389(2):295-300. PubMed ID: 19720046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M.
    Ode H; Neya S; Hata M; Sugiura W; Hoshino T
    J Am Chem Soc; 2006 Jun; 128(24):7887-95. PubMed ID: 16771502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.
    Clemente JC; Moose RE; Hemrajani R; Whitford LR; Govindasamy L; Reutzel R; McKenna R; Agbandje-McKenna M; Goodenow MM; Dunn BM
    Biochemistry; 2004 Sep; 43(38):12141-51. PubMed ID: 15379553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
    Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
    J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Within-host co-evolution of Gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 case.
    Shibata J; Sugiura W; Ode H; Iwatani Y; Sato H; Tsang H; Matsuda M; Hasegawa N; Ren F; Tanaka H
    Antiviral Res; 2011 Apr; 90(1):33-41. PubMed ID: 21338625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.
    Song W; Maeda Y; Tenpaku A; Harada S; Yusa K
    Antiviral Res; 2004 Mar; 61(3):173-80. PubMed ID: 15168798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H; Schön A; Freire E
    Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
    Prashar V; Bihani SC; Ferrer JL; Hosur MV
    Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
    Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
    J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.
    Mitsuya Y; Winters MA; Fessel WJ; Rhee SY; Hurley L; Horberg M; Schiffer CA; Zolopa AR; Shafer RW
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1300-5. PubMed ID: 17209774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
    Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
    BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.
    Stoffler D; Sanner MF; Morris GM; Olson AJ; Goodsell DS
    Proteins; 2002 Jul; 48(1):63-74. PubMed ID: 12012338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.